Around 5% of non-small-cell lung cancer patients using osimertinib monotherapy may experience severe cardiac adverse events, suggests a study of Japanese patients.
Carboplatin–pemetrexed plus pemetrexed maintenance is noninferior to docetaxel for the first-line treatment of advanced non-small-cell lung cancer in patients aged 75 years or older, suggests a phase 3 Japanese study.
Adding pembrolizumab to concurrent first-line chemoradiotherapy is tolerable and shows promising efficacy in patients with locally advanced non-small-cell lung cancer, according to phase 1 study data published in JAMA Oncology.
People with a current diagnosis or history of cancer may have an increased likelihood of developing COVID-19, with associated worse outcomes, suggests early research from China.
The improved outcomes associated with the addition of first-line pembrolizumab to chemotherapy are maintained over longer follow-up in patients with metastatic, nonsquamous non-small-cell lung cancer lacking EGFR or ALK alterations, indicate updated data from the KEYNOTE-189 trial.
The continuation of anticancer therapy may be feasible in patients who acquire SARS-CoV2, say the authors of a case report of a patient with advanced adenocarcinoma and COVID-19.
Disease progression among patients with metastatic lung, pancreatic, colorectal, and breast cancer is associated with statistically significant and clinically relevant reductions in health-related quality of life, real-world study data show.
Long-term follow-up findings from the KEYNOTE-010 trial support the use of a 2-year course of pembrolizumab for patients with previously treated advanced non-small-cell lung cancer positive for PD-L1 expression, the investigators believe.
Researchers have identified microRNA signatures that can potentially distinguish symptomatic patients with lung cancer from healthy people as well as those with other lung and non-lung diseases.
The PD-L1 inhibitor durvalumab, either given alone or alongside the CTLA-4 inhibitor tremelimumab, has clinical activity in the third- or later-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer, indicate ARCTIC trial results.
High BMI and normal albumin levels are associated with a reduced risk for grade 3 or higher chemotherapy-related toxicities among older patients, research indicates.
Immune checkpoint inhibitors achieve high response rates and prolonged overall survival among patients with pulmonary sarcomatoid carcinoma when used in the second- or later-line, report researchers.
Adding pembrolizumab to standard chemotherapy for advanced non-small-cell lung cancer has no detrimental effect on quality of life during or after treatment and results in better patient-reported outcomes than placebo, KEYNOTE-189 data show.
US researchers highlight the need for follow-up of stage IV non-small-cell lung cancer patients who receive first-line EGFR–tyrosine kinase inhibitor therapy, finding few patients subsequently undergo testing for the T790M mutation.
Use of a patient decision aid video improves informed decision-making about lung cancer screening among people accessing smoking cessation services in the USA, study findings indicate.
Individuals receiving atezolizumab for advanced non-small-cell lung cancer may have worse survival if they are also taking antibiotics or proton pump inhibitors, indicates an analysis of the POPLAR and OAK trials.
Individuals at high risk for developing lung cancer benefit from periodic screening with low-dose computed tomography, indicate the 10-year results from the NELSON trial.
Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.
Adding atezolizumab to carboplatin plus etoposide does not lead to substantially more adverse events than placebo and does not adversely affect health-related quality of life in patients with extensive-stage small-cell lung cancer, IMpower 133 trial data show.